Search
Searching Content indexed under Patent by Teresa Reguly ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
FCA Sends Differin Pricing Matter Back To PMPRB
The PMPRB is an administrative board established by the Patent Act with a mandate to protect Canadians from excessive drug pricing.
Canada
15 Aug 2019
2
Federal Court Of Appeal's Ruling On The Judicial Review Of PMPRB Decision On Differin
On June 28, the Federal Court of Appeal (FCA) affirmed the lower court's approach to patent review in determining whether the Patented Medicine Prices Review Board (PMPRB)
Canada
22 Jul 2019
3
Prosecution History Estoppel Comes To Canada
The December 2018 Royal Assent of Bill C-861 introduced new section 53.1 to the Patent Act, which brought prosecution history estoppel to Canada. This amendment removes the bar
Canada
28 Feb 2019
4
The USMCA: Good News For Intellectual Property Rights Holders
Canada's current intellectual property laws, including the imminent amendments to the Trademarks Act and Industrial Designs Act, are largely compliant with the obligations imposed by the USMCA.
Canada
17 Oct 2018
5
Free Trade Deal Reached After 11 Countries Sign CPTPP
The 11 countries part of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) signed the deal on March 8 in Santiago, Chile.
Canada
14 Mar 2018
6
Alexion Pharmaceuticals V Canada FCA Dismisses Appeal Aimed At Constitutionality Of PMPRB Provisions
The Federal Court of Appeal's decision in Alexion Pharmaceuticals Inc. v. Canada (Attorney General), 2017 FCA 241 has significant implications for patentees ...
Canada
27 Dec 2017
7
Proposed PMPRB Regulations Published For Comment
Amendments to the Patented Medicine Regulations (Proposed Regulations) were published for comment on December 1.
Canada
6 Dec 2017
8
Galderma Successful In Judicial Review Of PMPRB Decision On Differin
On November 9, the Federal Court issued its ruling on the judicial review of a decision by the Patented Medicine Prices Review Board (PMPRB) regarding the drug product Differin ...
Canada
17 Nov 2017
9
Alexion Ordered To Significantly Reduce Cost Of Soliris
On September 27, a two-member panel hearing of the PMPRB issued a rare excessive-pricing decision relating to the drug Soliris (eculizumab), manufactured by Alexion Pharmaceuticals Inc. (Alexion).
Canada
11 Oct 2017
10
Finalizing Patent Term Extension In Canada
The finalized Certificate of Supplementary Protection Regulations (CSP Regulations) were published in Canada Gazette, Part II on September 7 and will come into force on September 21.
Canada
21 Sep 2017
11
Canada Edges Toward Patent Term Extension
On July 15, the Government of Canada published its proposed Certificate of Supplementary Protection Regulations (Regulations)...
Canada
9 Aug 2017
12
Overhaul To Drug Pricing Regime Proposed In Canada
The Patented Medicine Prices Review Board published the consultation paper "Protecting Canadians from Excessive Drug Prices: Consulting on Proposed Amendments to the Patented Medicines Regulations."
Canada
13 Jun 2017
13
Generic Drug Manufacturers Not Off The Hook: Federal Court Of Appeal
This ruling continues the "merest slender thread of relevance" theme in Federal Court of Appeal jurisprudence which first appeared in the ICN decision.
Canada
30 Nov 2015
14
Federal Court Considers PMPRB Jurisdiction Over Generic Manufacturers
The Federal Court released two related decisions dealing with the jurisdiction of the Patented Medicine Prices Review Board over generic drugs.
Canada
14 Jul 2014
15
Look Before You Leap: Pre-Canadian Launch Regulatory Considerations For U.S. Companies
Deciding whether or not to launch a food, drug, medical device, dietary supplement or cosmetic product in Canada involves a number of considerations.
Canada
20 May 2014
16
CIPO's New Draft Guidelines Could Result In Higher Disclosure Standards For Canadian Patents
The Canadian Intellectual Property Office (CIPO) has released a further update to the Manual of Patent Office Practice (MOPOP), an administrative document of CIPO that examiners refer to during the patent examination process.
Canada
1 Dec 2009
17
Biosimilars In Canada: New Draft Guidelines From Health Canada
Health Canada announced that it had granted marketing authorization for Omnitrope (a human growth hormone), the first subsequent entry biologic (SEB) to be approved for sale in Canada.
Canada
22 Jul 2009
18
Canada´s Regulation Of Subsequent Entry Biologics
Health Canada has released a revised version of the draft guidance document "Information and Submission Requirements for Subsequent Entry Biologics".
Canada
8 Apr 2009
19
Follow-On Biologics In Canada
Health Canada has released a draft guidance document entitled "Information and Submission Requirements for Subsequent Entry Biologics (SEBs)."
Canada
3 Jun 2008
Links to Result pages
 
1